Discovered in 2000, NADA preferentially binds to the CB1 receptor. Like anandamide, NADA is also an agonist for the vanilloid receptor subtype 1 (TRPV1), a member of the vanilloid receptor family.
NADA, N-arachidonoyl-dopamine, Arachidonoyl dopamine, Anandamide dopamine, Endocannabinoid dopamine
